We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?
Read MoreHide Full Article
Zomedica Pharmaceuticals Corp. (ZOM - Free Report) will provide updates on its pipeline when it reports second-quarter 2020 results.
The company has a dismal earnings surprise history with its bottom line having missed expectations in two of the trailing four quarters, beating the same in one and witnessing break-even results on the remaining occasion. The average negative surprise is 8.33%. In the first quarter, the company reported in-line results.
Shares of Zomedica have decreased 4.3% in the year so far compared with the industry’s decline of 52.7%.
Let's see how things are shaping up for this announcement.
Factors to Consider
Zomedica, a veterinary diagnostic company,does not have any approved drug in its portfolio. In absence of any marketed drug, investors’focus will be on pipeline updates on second-quarter conference call.
The company deepens its focus on the final development and commercialization of Truforma, its inaugural point-of-care diagnostic biosensor platform, and the first five assays for the detection of adrenal and thyroid disorders in cats and dogs. In April this year, management announced completion of the verification of Truforma.
Targeting its Truforma platform, the company reduced administrative headcount and associated activities on account of which, general and administrative expense islikely to have declined in the Junequarter, indicating an improvementfrom the2019 levels.
What Our Model Indicates
Our proven model does not conclusively predict an earnings beat for Zomedica this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.
Earnings ESP: Zomedica has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 1 cent. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Zomedica currently carries a Zacks Rank #2.
Stocks to Consider
Here are some biotech stocks that have the right mix of elements to beat on earnings this time around:
bluebird bio Inc. (BLUE - Free Report) has an Earnings ESP of +69.18% and a Zacks Rank of 3 at present.
Amarin Corporation Plc. (AMRN - Free Report) has an Earnings ESP of +72.73% and is currently Zacks #3 Ranked.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Zomedica (ZOM) to Report Q2 Earnings: What's in the Cards?
Zomedica Pharmaceuticals Corp. (ZOM - Free Report) will provide updates on its pipeline when it reports second-quarter 2020 results.
The company has a dismal earnings surprise history with its bottom line having missed expectations in two of the trailing four quarters, beating the same in one and witnessing break-even results on the remaining occasion. The average negative surprise is 8.33%. In the first quarter, the company reported in-line results.
Shares of Zomedica have decreased 4.3% in the year so far compared with the industry’s decline of 52.7%.
Let's see how things are shaping up for this announcement.
Factors to Consider
Zomedica, a veterinary diagnostic company,does not have any approved drug in its portfolio. In absence of any marketed drug, investors’focus will be on pipeline updates on second-quarter conference call.
The company deepens its focus on the final development and commercialization of Truforma, its inaugural point-of-care diagnostic biosensor platform, and the first five assays for the detection of adrenal and thyroid disorders in cats and dogs. In April this year, management announced completion of the verification of Truforma.
Targeting its Truforma platform, the company reduced administrative headcount and associated activities on account of which, general and administrative expense islikely to have declined in the Junequarter, indicating an improvementfrom the2019 levels.
What Our Model Indicates
Our proven model does not conclusively predict an earnings beat for Zomedica this season. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat. But that is not the case here as you will see below.
Earnings ESP: Zomedica has an Earnings ESP of 0.00% as both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at a loss of 1 cent. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Zomedica currently carries a Zacks Rank #2.
Stocks to Consider
Here are some biotech stocks that have the right mix of elements to beat on earnings this time around:
ACADIA Pharmaceuticals Inc. (ACAD - Free Report) has an Earnings ESP of +4.23% and a Zacks Rank #3, presently. You can see the complete list of today’s Zacks #1 Rank stocks here.
bluebird bio Inc. (BLUE - Free Report) has an Earnings ESP of +69.18% and a Zacks Rank of 3 at present.
Amarin Corporation Plc. (AMRN - Free Report) has an Earnings ESP of +72.73% and is currently Zacks #3 Ranked.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>